1093.HK

CSPC Pharmaceutical Group Ltd. (1093.HK) warned on Thursday that is net profit for the first nine months of this year fell about 16% compared with a year earlier.

It blamed the decline on falling revenue for its oncology and cardiovascular therapeutic drugs, which were down about 18% and 11%, respectively, year-on-year during the period. Those declines were partially offset by a 4% rise in revenue from its nervous system therapeutic drug sales. CSPC’s shares fell 13% to HK$5 in early Friday trade.

By A. Au

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Kelun-Biotech reported rising sales of its signature cancer drug

Precision cancer drugs show promise for Kelun-Biotech

The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…